4M THERAPEUTICS INC.
4M Therapeutics Inc. is a biotechnology startup dedicated to developing targeted therapies for neuropsychiatric and neurodegenerative conditions by utilizing living human brain cells derived from induced pluripotent stem cells. Their mission is to identify and optimize candidate medicines that modulate key pathways involved in neuronal health, such as neuroplasticity, neurogenesis, and neuroinflammation, aiming to improve the lives of patients with CNS disorders.
Industries
Nr. of Employees
small (1-50)
4M THERAPEUTICS INC.
Products
GSK3β inhibitor candidate (lead clinical candidate)
A lead small-molecule GSK3β inhibitor discovered via human iPSC-derived cell screening; described as the primary metabolite of a previously studied compound with improved GSK3β potency, selectivity, and CNS PK/PD supportive of once-daily dosing and Phase 1 entry.
GSK3β inhibitor series for Alzheimer’s agitation
A series of potent and selective GSK3β inhibitors developed for potential treatment of agitation in Alzheimer’s disease and related indications.
Peptide CDK5/p25 inhibitor series for neurodegeneration
A peptide-based inhibitor series targeting hyperactivated CDK5/p25 with preclinical data showing rescue of learning and memory deficits and reduction in microgliosis and neuronal loss in aged tau pathology models.
GSK3β inhibitor candidate (lead clinical candidate)
A lead small-molecule GSK3β inhibitor discovered via human iPSC-derived cell screening; described as the primary metabolite of a previously studied compound with improved GSK3β potency, selectivity, and CNS PK/PD supportive of once-daily dosing and Phase 1 entry.
GSK3β inhibitor series for Alzheimer’s agitation
A series of potent and selective GSK3β inhibitors developed for potential treatment of agitation in Alzheimer’s disease and related indications.
Peptide CDK5/p25 inhibitor series for neurodegeneration
A peptide-based inhibitor series targeting hyperactivated CDK5/p25 with preclinical data showing rescue of learning and memory deficits and reduction in microgliosis and neuronal loss in aged tau pathology models.
Services
Provision of research compounds for external studies
Supplying novel small molecules to academic and industry collaborators for preclinical testing and target validation under collaborative agreements.
Provision of research compounds for external studies
Supplying novel small molecules to academic and industry collaborators for preclinical testing and target validation under collaborative agreements.
Expertise Areas
- Neuroscience drug discovery
- Stem cell-based phenotypic screening
- Medicinal chemistry for kinase inhibitors
- Preclinical in vivo pharmacology
Key Technologies
- Induced pluripotent stem cell (iPSC)-derived neural models
- Phenotypic high-content screening
- Kinetic image cytometry
- Small-molecule GSK3β inhibition